13F Pro13F Pro

Deep Track Capital, LP

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1856083
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare100.0%$6.8B

AUM History

13fpro.ai/research/fund/deep-track-capital-lp-1856083

Conviction and streaks

Diversifying · top 10 = 40.1%

From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.

GH$GHConviction hold7.5% weight · held 10 quartersIMVT$IMVTConviction hold5.3% weight · held 10 quartersGPCR$GPCRConviction hold3.8% weight · held 10 quartersPCVX$PCVXConviction hold3.7% weight · held 6 quartersTARS$TARSConviction hold3.4% weight · held 6 quartersTARS$TARSAccumulating+147% shares · 5 quarters runningTNGX$TNGXAccumulating+189% shares · 3 quarters runningBCAX$BCAXAccumulating+69% shares · 3 quarters runningCOGT$COGTAccumulating+549% shares · 3 quarters runningGH$GHAccumulating+21% shares · 2 quarters runningORKA$ORKATrimming-28% shares · 3 quarters runningCYTK$CYTKTrimming-84% shares · 3 quarters runningAXSM$AXSMTrimming-39% shares · 2 quarters runningMBX$MBXTrimming-47% shares · 2 quarters runningDYN$DYNTrimming-43% shares · 2 quarters running

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/deep-track-capital-lp-1856083

Deep Track Capital, LP 13F holdings — Q2 2026

$6.9B portfolio (+12.2% QoQ) · 67 holdings · Q2 2026 13F · top 10 are 40% of the stock portfolio

Includes $82.4M of put/call options ($0 puts, $82.4M calls), which 13F rules report at the value of the underlying shares, not the premium at risk. Stocks alone: $6.8B. Weights use the stock portfolio.

All holdings — Deep Track Capital, LP (Q2 2026)

67 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
BMRN$BMRNBIOMARIN PHARMACEUTICAL INC$189.3M+188%
NRIX$NRIXNurix Therapeutics, Inc.$187.7M+22%
ORKA$ORKAOruka Therapeutics, Inc.$183.3M-5%
ALMS$ALMSALUMIS INC.$178.6M-6%
IONS$IONSIONIS PHARMACEUTICALS INC$174.4M+13%
CMPS$CMPSCOMPASS Pathways plcadr$172.1M—
VERA$VERAVera Therapeutics, Inc.$171.6M-3%
AXSM$AXSMAxsome Therapeutics, Inc.$171.3M-36%
GMAB$GMABGENMAB A/Sadr$155.2M+54%
MLTX$MLTXMoonLake Immunotherapeutics$136.3M+9%
COAG$COAGHemab Therapeutics Holdings, Inc.$132.3MNew
TNGX$TNGXTango Therapeutics, Inc.$131.3M+53%
DFTX$DFTXDefinium Therapeutics, Inc.$129.4M-8%
GRAL$GRALGRAIL, Inc.$125.3M+7%
BCAX$BCAXBicara Therapeutics Inc.$121.7M+0.9%

What changed in Q2 2026

Against the previous quarter's 13F: 19 new, 22 added to, 15 trimmed, 15 sold out. Share-count changes; largest moves by dollar size first.

New positions (19)

  • ALNY$ALNYALNYLAM PHARMACEUTICALS, INC.$248.3M

    first bought this quarter

  • COAG$COAGHemab Therapeutics Holdings, Inc.$132.3M

    first bought this quarter

  • GHRS$GHRSGH Research PLC$89.6M

    first bought this quarter

  • GMAB$GMABCALLGENMAB A/S$82.4M

    first bought this quarter

  • UTHR$UTHRUNITED THERAPEUTICS Corp$67.0M

    first bought this quarter

  • AVTX$AVTXAvalo Therapeutics, Inc.$66.7M

    first bought this quarter

+13 more in the Excel export

Added to (22)

  • MANE$MANEVeradermics, Inc+300%

    now $245.9M · held 2 qtrs, 2 adds in a row

  • BMRN$BMRNBIOMARIN PHARMACEUTICAL INC+188%

    now $189.3M · held 4 qtrs

  • CLDX$CLDXCelldex Therapeutics, Inc.+129%

    now $109.4M · held 7 qtrs

  • GMAB$GMABGENMAB A/S+54%

    now $155.2M · held 2 qtrs, 2 adds in a row

  • NUVL$NUVLNuvalent, Inc.+30%

    now $220.2M · held 2 qtrs, 2 adds in a row

  • TNGX$TNGXTango Therapeutics, Inc.+53%

    now $131.3M · held 4 qtrs, 4 adds in a row

+16 more in the Excel export

Trimmed (15)

  • AXSM$AXSMAxsome Therapeutics, Inc.-36%

    now $171.3M · held 5 qtrs, 2 trims in a row

  • IMVT$IMVTImmunovant, Inc.-19%

    now $359.9M · held 10+ qtrs

  • CYTK$CYTKCYTOKINETICS INC-49%

    now $59.6M · held 9 qtrs, 3 trims in a row

  • MBX$MBXMBX Biosciences, Inc.-37%

    now $95.6M · held 8 qtrs, 2 trims in a row

  • IMCR$IMCRImmunocore Holdings plc-84%

    now $9.9M · held 7 qtrs, 2 trims in a row

  • ALMS$ALMSALUMIS INC.-6%

    now $178.6M · held 2 qtrs

+9 more in the Excel export

Sold out (15)

  • PUTSPDR SERIES TRUSTwas $1.3B
  • APLS$APLSApellis Pharmaceuticals, Inc.was $182.3M

    held 9+ qtrs

  • CNTA$CNTACentessa Pharmaceuticals plcwas $125.4M

    held 2 qtrs

  • BBIO$BBIOBridgeBio Pharma, Inc.was $62.5M

    held 6 qtrs

  • TERN$TERNTerns Pharmaceuticals, Inc.was $56.6M

    held 9+ qtrs

  • GERN$GERNGERON CORPwas $47.3M

    held 9+ qtrs

+9 more in the Excel export

Firm AUM (Form ADV): $8.4B as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F Deep Track Capital, LP has filed, 18 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Deep Track Capital?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of Deep Track Capital's top 20 holdings: 38/100 (our AI quality score, weighted by position size; 10 of the 20 are scored)

Top 10 since filing

-9.8%

Value-weighted move of the 10 largest stock positions

Turnover

18%

Last quarter; 74% over the last 4

Top 10 weight

40%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

56%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Deep Track Capital, LP disclosed 67 positions worth $6.9B in its Form 13F-HR for Q2 2026 — $6.8B in common stock plus $82.4M of put/call option positions (reported at underlying notional value, not premium at risk), led by $GH (Guardant Health, Inc.) at 7.5% of the equity portfolio, followed by $IMVT and $GPCR. During the quarter the fund opened 19 new positions and exited 15 — including a new stake in $ALNY. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Deep Track Capital, LP’s Form 13F-HR filing with the SEC under CIK 1856083.

Funds like this

managers whose biggest positions overlap Deep Track Capital's
Paradigm Biocapital Advisors LP$5.34B 13F book · 9 shared top holdingsGMABTARSNUVLALNYRTW INVESTMENTS, LP$11.71B 13F book · 11 shared top holdingsORKATNGXGHTARSDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)$9.59B 13F book · 9 shared top holdingsNUVLIONSGMABVERARA CAPITAL MANAGEMENT, L.P.$11.51B 13F book · 9 shared top holdingsPCVXCOAGBCAXNUVLLogos Global Management LP$2.32B 13F book · 13 shared top holdingsVERAOCULMLTXTNGXAvoro Capital Advisors LLC$11.14B 13F book · 10 shared top holdingsGPCRVERADFTXOCUL

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Deep Track Capital, LP

13F Pro is an AI hedge fund tracker and stock research platform. For Deep Track Capital, LP (SEC CIK: 1856083), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Deep Track Capital, LP's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.